Abstract:Epidermal growth factor receptors (EGFR) are overexpressed in triple-negative breast cancer (TNBC) and are an attractive target for the development of theranostic radiopharmaceuticals. We studied anti-EGFR panitumumab labeled with 111In (panitumumab-DOTA-111In) for SPECT/CT imaging and Meitner-Auger electron (MAE) radioimmunotherapy (RIT) of TNBC. Panitumumab-DOTA-111In was bound, internalized, and routed to the nucleus in MCF7, MDA-MB-231/Luc, and MDA-MB-468 human breast cancer (BC) cells dependent on the EGFR expression level (1.5 × 104, 1.7 × 105, or 1.3 × 106 EGFR/cell, respectively). The absorbed dose in the nuclei of MCF7, MDA-MB-231/Luc, and MDA-MB-468 cells incubated with 4.4 MBq of panitumumab-DOTA-111In (20 nM) was 1.20 ± 0.02, 2.2 ± 0.1, and 25 ± 2 Gy, respectively. The surviving fraction (SF) of MDA-MB-231/Luc cells treated with panitumumab-DOTA-111In (10-300 nM; 1.5 MBq/μg) was reduced as the absorbed dose in the cell increased, with clonogenic survival reduced to an SF = 0.12 ± 0.05 at 300 nM corresponding to 12.7 Gy. The SFs of MDA-MB-468, MDA-MB-231/Luc, and MCF7 cells treated with panitumumab-DOTA-111In (20 nM; 1.7 MBq/μg) were <0.01, 0.56 ± 0.05, and 0.67 ± 0.04, respectively. Unlabeled panitumumab had no effect on SF, and irrelevant IgG-DOTA-111In only modestly reduced the SF of MDA-MB-231/Luc cells but not MCF7 or MDA-MB-468 cells. The cytotoxicity of panitumumab-DOTA-111In was mediated by increased DNA double-strand breaks (DSB), cell cycle arrest at G2/M-phase and apoptosis measured by immunofluorescence detection by flow cytometry. MDA-MB-231/Luc tumors in the mammary fat pad (MFP) of NRG mice were clearly imaged with panitumumab-DOTA-111In by microSPECT/CT at 4 days postinjection (p.i.), and biodistribution studies revealed high tumor uptake [18 ± 2% injected dose/g (% ID/g] and lower normal tissue uptake (<10% ID/g). Administration of up to 24 MBq (15 μg) of panitumumab-DOTA-111In to healthy NRG mice caused no major hematological, renal, or hepatic toxicity with no decrease in body weight. Treatment of NOD SCID mice with MDA-MB-231 tumors with panitumumab-DOTA-111In (22 MBq; 15 μg) slowed tumor growth. The mean time for tumors to reach a volume of ≥500 mm3 was 61 ± 5 days for RIT with panitumumab-DOTA-111In compared to 42 ± 6 days for mice treated with irrelevant IgG2-DOTA-111In (P < 0.0001) and 35 ± 3 days for mice receiving 0.9% NaCl (P < 0.0001). However, tumors regrew at later time points. The median survival of mice treated with panitumumab-DOTA-111In was 70 days versus 46 days for IgG2-DOTA-111In (P < 0.0001) or 40 days for 0.9% NaCl (P < 0.0001). We conclude that panitumumab-DOTA-111In is a promising theranostic agent for TNBC. Increasing the administered amount of panitumumab-DOTA-111In and/or combination with radiosensitizing PARP inhibitors used for treatment of patients with TNBC may provide a more durable response to RIT.

MicroSPECT Imaging of Triple Negative Breast Cancer Cell Tumor Xenografted in Athymic Mice with Radioiodinated Anti-Icam-1 Monoclonal Antibody

ICAM1-Targeting Theranostic Nanoparticles for Magnetic Resonance Imaging and Therapy of Triple-Negative Breast Cancer

ICAM-1 As a Molecular Target for Triple Negative Breast Cancer.

Radioimmunoimaging and Targeting Treatment in an Immunocompetent Murine Model of Triple-Negative Breast Cancer Using Radiolabeled Anti-Programmed Death-Ligand 1 Monoclonal Antibody

99mTc-labeled iRGD for single-positron emission computed tomography imaging of triple-negative breast cancer

Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer

Development and Characterization of CD54-targeted Immunopet Imaging in Solid Tumors.

800CW Dye and 89zr Dual-labeled Antibody for the PET/NIRF/Cerenkov Multi-modality Imaging of ICAM-1 (CD54) in Pancreatic Cancer

Radioimmunolocalization and blodistribution of 131Ⅰ labeled anti-CEA,TPS and mixture monoclonal antibody in nude mice bearing human breast cancer xenografts

Radioimmunoimaging and Biodistribution of ~(131)I Labeled Anti-Cea Monoclonal Antibody C50 in Nude Mice Bearing Human Breast Carcinoma Xenografts

Local Radioimmunotherapy of Breast Cancer-Bearing Nude Mice Using Anti-Cea Monoclonal Antibody C50 Labeled with 131I

MicroPET-CT Evaluation of Interstitial Brachytherapy in Pancreatic Carcinoma Xenografts

Molecular Imaging of Tumor-Infiltrating Macrophages in a Preclinical Mouse Model of Breast Cancer.

Multimodality Imaging Of Breast Cancer Experimental Lung Metastasis With Bioluminescence And A Monoclonal Antibody Dual-Labeled With Zr-89 And Irdye 800cw

Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer

The Combined Therapeutic Effects of 131Iodine-Labeled Multifunctional Copper Sulfide-Loaded Microspheres in Treating Breast Cancer.

Radioimmunoimaging and Biodistribution of 131I-Herceptin in Breast Cancer Xenograft BALB/c-neu Mousse

Specific diagnosis of lymph node micrometastasis in breast cancer by targeting activatable near-infrared fluorescence imaging

In Vivo Near-Infrared Fluorescence Imaging of CD105 Expression During Tumor Angiogenesis

Micro PET imaging of 18F-Fluoromisonidazole in an MDA-MB-231 triple negative human breast cancer xenograft model

Panitumumab-DOTA-111In: An Epidermal Growth Factor Receptor Targeted Theranostic for SPECT/CT Imaging and Meitner-Auger Electron Radioimmunotherapy of Triple-Negative Breast Cancer